Crohn’s Disease: Early Diagnosis with Intestinal Ultrasound
Intestinal ultrasound (IUS) emerges as a game-changer in the early management of Crohn’s disease, offering a non-invasive method too predict remission. According to a recent study, IUS shows that improvements in IUS parameters within the first year correlate with enhanced patient outcomes, specifically with over a third of patients achieving remission within months. this innovative approach coudl vastly improve patient management by informing therapy decisions early in the diagnostic process.Researchers found that while early identification of patients at risk led to more effective therapy decisions, factors like a higher body mass index could affect remission rates. Discover how News Directory 3 is following these crucial advances in gastroenterology,and stay tuned to learn about the optimal timing for transmural healing assessment in the world of IUS.
Intestinal Ultrasound Shows Promise in Predicting Crohn’s Disease Remission
Updated June 04, 2025
Intestinal ultrasound (IUS) is proving to be a valuable tool in predicting remission for individuals recently diagnosed with Crohn’s disease (CD).A recent study in Denmark highlights the potential of this non-invasive imaging technique in monitoring disease activity right from the start.
The multicenter study, led by Dr. Gorm R. Madsen from Copenhagen University Hospital, tracked patients with new-onset Crohn’s disease. Researchers found that improvements in IUS parameters during the first year of diagnosis correlated with positive outcomes. Specifically, about 38% of patients achieved ultrasonic transmural remission within three months, which was linked to sustained steroid-free clinical remission and a reduced need for escalating treatment.
Madsen emphasized the importance of these findings, stating that IUS can improve patient management and risk stratification early on. The study suggests that early identification of patients at risk could lead to more effective therapy decisions.
From May 2021 to April 2023, the study followed 201 patients with new adult-onset CD, using IUS alongside symptomatic, biochemical, and endoscopic evaluations. The results indicated that transmural remission at three months was more common in patients with colonic disease. Interestingly, there was no connection between sonographic inflammation at diagnosis and delays in diagnosis.
“Nearly 40% of newly diagnosed Crohn’s patients achieved transmural remission within 3 months — a higher proportion than seen in earlier studies… It was also striking how strongly early IUS findings predicted the need for surgery, outperforming endoscopy and biomarkers,” Madsen said.
The study also revealed that a higher body mass index at baseline reduced the likelihood of achieving transmural remission at 12 months. Additionally, the International Bowel Ultrasound Segmental Activity Score in the terminal ileum at diagnosis proved to be the best predictor of ileocecal resection during the first year.
Anna L. Silverman,a gastroenterology fellow at Icahn School of Medicine at Mount Sinai,noted that the study reinforces the value of IUS as a tool to guide early management decisions in Crohn’s disease.Ashwin ananthakrishnan, director of the Crohn’s and Colitis Center at Massachusetts General Hospital, added that the study highlights the importance of early transmural healing in determining outcomes.
What’s next
Further research is needed to determine the optimal timing for transmural healing assessment and the added value of IUS compared to other markers. However, the current findings suggest that intestinal ultrasound offers a promising, non-invasive approach to managing Crohn’s disease and improving patient outcomes.